Bryan, Garnier & Co

🗝️ What are some key takeaways from M&A internships? Meet some of our interns, whose journey at Bryan Garnier has been a gateway into a lucrative career in investment banking. Here's to nurturing talent and fostering a culture of continuous growth! Check out our current internship opportunities here: https://lnkd.in/eAsvKhm #GrowthMindset #InternExcellence #BryanGarnierGrowth #UnleashingPotential Jérôme Lenay, Nicolas Plovier, Candice Curlier, Willy Guilleminot, Malek Sabri, Mattéo Delalande, Théophile Larbre Delmas, Guillaume Thomazeau, Thomas Hynes, Mohamed El Hachemi, Valentin C.

💻 Join us on Tuesday 23rd July to hear about the latest developments in secondaries and the evolution of company-led liquidity. 🔗 https://lnkd.in/eaE7eh9z  The European secondary market is quickly gaining popularity and attracting both new and existing investors. This shift indicates the maturation of venture capital and reflects a transformative shift as stakeholders adapt to new liquidity needs and market dynamics. Learn more in our upcoming White Paper "Demystifying company-led secondaries" and join our exclusive accompanying webinar on 23rd July where former-NotSoLiquid co-founders David and Pierre delve into: 📈 The market overview: Navigating VC secondaries in 2024 🎯 Company-led liquidity strategies and best practices 💰 Use cases and investor landscape Don’t miss this opportunity to learn more about this topic in our webinar – register now 🔗 https://lnkd.in/eaE7eh9z #VentureCapital #SecondaryMarkets #WhitePaper #Webinar #BryanGarnier

🛰️ How will Amazon's Kuiper overcome the challenges in its race against SpaceX's Starlink? 💬 BG IRIS Research Associate Antoine Lebourgeois, CFA recently shared insights with Capucine Cousin in L'AGEFI about the recent approval for deploying Amazon’s Kuiper satellites in France. Find out what Amazon needs to do to catch up to SpaceX! 🔗 Explore the key takeaways in English here: https://lnkd.in/eWgKUqBu 📰 For French speakers, read the article here: https://lnkd.in/eEVNwUhv #SpaceIndustry #Satellites #SpaceX #Amazon #BGIRIS #LAGEFI

Did you know that home haemodialysis patients can save up to 52 days per year through reduced recovery, travel, and appointment wait times? https://lnkd.in/ecmDY-VW  ⚕️ Having administered over 1 million treatments with their S3 monitor and currently serving 1100 home patients daily, PHYSIDIA is at the forefront of home haemodialysis solutions. In our interviews with Physidia’s leaders and investors, we explored their dedication to transforming healthcare perceptions, enhancing patient quality of life, and effectively managing conditions. 🌎 Looking ahead, Physidia is expanding into new European, Middle Eastern, and US markets, advancing R&D for next-generation devices, and leveraging data to improve home care. Welcome to the “BG Growth Series”, where entrepreneurs tell us about their inspiring stories, share invaluable insights, and offer practical tips to navigate the growth journey. 🔗 See the full episode here: https://lnkd.in/ecmDY-VW  Didier Candelot, Nicolas P., Julien Dolivet, Rory Devlin, Charles Nantois Olivier Garnier, Hervé Ronin, Paul de Mestier, Raphaël Bidaut, Mark (Min-Woo) Hong #HomeDialysis #HealthcareInnovation #Physidia #BryanGarnier #PatientCare

🚀 How do you turn innovation into world-changing success? https://lnkd.in/ek_bBnJB We had the privilege to interview Anne Glover, CEO and Co-Founder of Amadeus Capital Partners, about her journey in venture capital, covering topics such as: 🎯 Mastering your trade  📉 Creating value in tough market conditions  🌱 The maturity of the VC ecosystem in the US compared to the EU Anne’s insights are a reminder of the importance of persistence in driving innovation. #VentureCapital #Entrepreneurship #Innovation #Leadership #BryanGarnier

🛰️ Did you know that Starlink (SpaceX) and Kuiper (Amazon) are expected to collectively represent nearly 95% of the capacity deployed by commercial constellations by 2030? 🔗 https://lnkd.in/e2CpMjYp 📡 When considering the mass launched into orbit, megaconstellations emerge as an unprecedented phenomenon within the space industry landscape, distinctly centered around Starlink and Kuiper. In our latest Industry Report "Satcoms’ Muskonomics", Antoine Lebourgeois, CFA delves into the dynamic landscape of satcoms, unveiling the intricate interplay between its main actors. To dive deep into this topic and discover more about the changes affecting the satcoms market, download the industry brief here 👉 https://lnkd.in/e2CpMjYp   Florent Roulet, Antony Northrop, Fraser Wood, Paul Charpentier, Aurélien Deside

When we think of natural medicine, we inevitably think of the century-old Boiron France, a world leader in natural medicine that has spearheaded the industry's global development. 🔗 https://lnkd.in/epprYTpH 🎥 We sat down with Thierry Boiron, President and Chairman of Boiron to learn more about the company’s constant innovation and adaptability. 🌎 Their partnership with the US growth equity fund EW Healthcare Partners marks a significant step in Boiron’s growth and mission to continue transforming lives globally with a holistic and ecological approach to medicine. Welcome to the “BG Growth Series”, where entrepreneurs tell us about their inspiring stories, share invaluable insights, and offer practical tips to navigate the growth journey. Olivier Garnier, Hervé Ronin, Raphaël Bidaut, Hamza Falah, Jonathan Pavillard, Léa Maufras-Lenoël Paul de Mestier, Pierre-Georges Roy, Vincent Meunier, Romain Ellul, Ahmed Soibah-Eddine, Mickael Dubourd, Mark (Min-Woo) Hong, Slim H., Gustaf Orsucci, Francesco M. Delorenzi, Zhe Qu, Danielle Glickstein, Hamza Falah, Michael Tuller, Victor Tramier, Nils Nyberg, Axel Gonnon, Othmane El Hajjaji, Max Lopez, Maëva Cariven, Wladimir Boutet, Quentin Vu #NaturalMedicine #HealthcareInvestment #Boiron #BryanGarnier

🏞️ Last week's exclusive networking event gathered 50 entrepreneurs, investors, and corporate executives to cruise down the Isar river in Munich as part of Bryan, Garnier & Co’s 7th annual River Raft Event! From the early morning departure to the final splashdown, the day was filled with engaging conversations against the picturesque backdrop of the Bavarian countryside and the Isar river. A big thank you to everyone who joined us and made the event memorable. We're already looking forward to next year’s journey! Check out some photos from the event 👇 #BryanGarnier #NetworkingEvent #Munich #InvestmentBanking 

We asked Jonathan while it’s still fresh: How do you get to a Partner position at a global growth investment bank at 36 years old? 🔗 https://lnkd.in/gBXMP7hV Jonathan started working at Bryan, Garnier & Co nearly ten years ago as an Associate. Within his first year at the firm, he was promoted to Vice President, then to Managing Director in 2021, and then became a Partner in 2024. We had the opportunity to sit down with Jonathan as part of our Employee Growth Stories and learn more about his career growth, what keeps him motivated and his outlook for the practice. 🔗 Read Jonathan’s full story here: https://lnkd.in/gBXMP7hV #CareerDevelopment #BryanGarnier #InvestmentBanking #GrowthMindset

🌐 Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on Swedish Cinclus Pharma’s SEK 715m Nasdaq Stockholm IPO. More about the deal: https://lnkd.in/eUZhJ9fz   ⚕️ This is the first Swedish Main Market sizeable biotech IPO in 6 years after the IPO of Calliditas Therapeutics in June 2018. The late-stage biopharmaceutical company develops therapeutic treatments for severe and erosive forms of gastroesophageal reflux disease (GERD) with its proprietary lead drug candidate, linaprazan glurate.   Cinclus Pharma intends to use the proceeds of the offering to prepare, initiate, and complete the first Phase 3 study of linaprazan glurate for erosive GERD, conduct additional preclinical studies for market registration, and finance regulatory activities and ongoing operations.   This marks another landmark transaction for Bryan, Garnier & Co’s Capital Markets franchise in the Nordics, after the Camurus’ SEK 1.1bn follow-on and Egetis Therapeutics AB Therapeutics’ SEK 462m combined follow-on offerings, as well as Calliditas Therapeutics’ EUR 92m senior secured debt facility. A big thanks to the Cinclus Pharma’s team for their trust: Christer Ahlberg, Jesper Wiklund, Peter Wallich, Peter Unge, Lennart Hansson and Kjell Andersson #Healthcare #Biotech #GERD #IPO #CinclusPharma #BryanGarnier   Pierre Kiecolt-Wahl, Vincent Meunier, Paul Lequeux, Gustaf Orsucci, Theodore de Charsonville, Camille Dubroc, Oscar Haffen Lamm